Guardant Health shares are trading higher after the company announced that the FDA Advisory Committee Panel recommends approval of Shield blood test for colorectal cancer screening.
Portfolio Pulse from Benzinga Newsdesk
Guardant Health shares are trading higher after the company announced that the FDA Advisory Committee Panel recommends approval of Shield blood test for colorectal cancer screening.
May 24, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health shares are trading higher following the FDA Advisory Committee Panel's recommendation to approve the Shield blood test for colorectal cancer screening.
The FDA Advisory Committee Panel's recommendation is a significant regulatory milestone for Guardant Health's Shield blood test, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100